An Act To Amend Title 16 Of The Delaware Code Relating To Certificate Of Public Review.
Summary
HB17 amends Delaware’s Certificate of Public Review law in Title 16, which governs state review of certain health-care facility projects before they can proceed. The bill updates the definition of “major medical equipment” and clarifies when a Certificate of Public Review is required for health-care facility construction, capital expenditures, bed-capacity changes, and the acquisition or use of major medical equipment. It also preserves existing exemptions for certain equipment and facilities, such as replacement equipment, some employee- or school-based first aid stations, and freestanding acute inpatient rehabilitation hospitals.
A key substantive change is the adjustment of the capital expenditure threshold to more than $5.8 million, with future increases tied to inflation using a federal labor index. The bill also allows the Board to exempt certain capital expenditures for facility maintenance that are not related to direct patient care, and it gives the Board discretion to exempt some acquisitions of major medical equipment not yet available in Delaware. The act is scheduled to take effect on July 1, 2026, giving health-care providers and regulators time to prepare for the revised review standards.
Impact
HB17 modifies the state’s health-care facility review framework by changing the statutory triggers for Certificate of Public Review oversight under Title 16, Chapter 93. It affects hospitals, health-care facilities, nonprofit facility acquisitions, and entities acquiring or using major medical equipment in Delaware, while also expanding or clarifying Board authority to grant exemptions in limited circumstances. The bill does not eliminate review; rather, it refines which projects and equipment purchases are subject to state approval and updates the dollar threshold and inflation-adjustment mechanism.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed the House 40-0 and the Senate 19-0, indicating unanimous approval in both chambers. The sponsor list also includes members from both parties, suggesting the measure was viewed as a technical or policy update to an existing regulatory process rather than a controversial overhaul.
Contention
No committee testimony or floor debate is provided, and the recorded votes show no opposition, so there is no documented contention in the available materials. The most likely policy questions raised by the bill would concern whether the higher capital expenditure threshold reduces regulatory burden too much, whether the Board’s exemption authority is broad enough, and how the changes affect hospital expansion, equipment acquisition, and health-care market oversight. However, the available record does not show any organized opposition or specific disputed provisions.